background
viral
lower
respiratori
tract
ill
lrti
frequent
caus
adult
hospit
link
antibiot
overus
european
studi
suggest
serum
procalcitonin
pct
level
may
use
guid
antibiot
therapi
conduct
trial
assess
feasibl
use
pct
algorithm
viral
test
guid
antibiot
use
us
hospit
method
three
hundr
patient
hospit
nonpneumon
lrti
octob
randomli
assign
ratio
receiv
standard
care
pctguid
care
viral
pcr
test
primari
outcom
antibiot
exposur
safeti
assess
month
result
among
patient
intervent
group
virus
identifi
pct
valu
signific
differ
antibiot
use
advers
event
intervent
patient
nonintervent
group
subgroup
analys
reveal
fewer
subject
posit
result
viral
test
low
pct
valu
discharg
receiv
antibiot
vs
p
shorter
antibiot
durat
among
algorithmadher
intervent
patient
versu
nonintervent
patient
vs
day
p
compar
histor
control
antibiot
durat
nonintervent
patient
decreas
day
vs
day
p
suggest
studi
effect
conclus
although
antibiot
use
similar
arm
subgroup
analys
intervent
patient
suggest
physician
respond
viral
biomark
data
data
inform
design
futur
us
studi
clinic
trial
registr
lower
respiratori
tract
infect
lrti
commonli
caus
adult
hospit
virus
account
mani
ill
increas
avail
multiplex
polymeras
chain
reaction
pcr
assay
allow
clinic
laboratori
rapidli
detect
wide
varieti
respiratori
virus
despit
viral
detect
patient
us
hospit
receiv
broadspectrum
antibiot
partli
concern
bacteri
coinfect
report
europ
suggest
elev
serum
procalcitonin
pct
level
predict
bacteri
infect
pct
algorithm
use
safe
guid
antibiot
use
lrti
result
signific
reduct
antibiot
durat
howev
pctbase
treatment
algorithm
respiratori
infect
wide
adopt
unit
state
prior
studi
adult
hospit
respiratori
ill
show
viral
infect
common
virus
evid
bacteri
infect
although
receiv
antibiot
result
posthoc
physician
survey
indic
percept
serum
biomark
coupl
viral
test
would
help
guid
antibiot
decis
nevertheless
confid
pctguid
algorithm
among
us
physician
like
iter
process
moreov
earli
diagnosi
treatment
antibiot
recommend
profession
societi
patient
hospit
pneumonia
mandat
clinic
practic
potenti
prevent
inappropri
antibiot
use
set
viral
lrti
like
greatest
popul
patient
without
clinic
diagnost
evid
definit
pneumon
process
therefor
believ
initi
us
clinic
trial
pctguid
care
lrti
focu
person
lower
risk
invas
bacteri
diseas
without
definit
pneumonia
thu
investig
feasibl
conduct
pctbase
algorithm
trial
us
hospit
valu
concurr
viral
test
reduc
unnecessari
antibiot
use
adult
hospit
nonpneumon
lrti
trial
design
open
label
random
clinic
trial
patient
hospit
nonpneumon
lrti
random
standard
care
pctguid
care
combin
multiplex
viral
pcr
test
trial
regist
clinicaltrialsgov
rochest
gener
hospit
rgh
commun
hospit
rochest
new
york
studi
site
rgh
use
electron
medic
record
emr
inpati
care
staff
depart
intern
medicin
duplex
pcr
influenza
viru
respiratori
syncyti
viru
rsv
hereaft
hospit
pcr
routin
avail
pct
test
avail
patient
intens
care
unit
icu
rgh
also
site
previou
respiratori
ill
surveil
studi
conduct
studi
popul
inclus
criteria
ident
present
studi
prior
studi
physician
midlevel
provid
nurs
practition
physician
assist
formal
educ
regard
result
previou
surveil
studi
caus
respiratori
infect
antibiot
guidelin
antibiot
complic
use
pct
algorithm
guid
antibiot
therapi
adult
year
age
symptom
compat
lrti
ie
admiss
diagnosi
pneumonia
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
bronchiti
asthma
influenza
viral
syndrom
respiratori
failur
congest
heart
failur
chf
identifi
review
daili
admiss
censu
patient
characterist
indic
high
risk
bacteri
infect
ie
icu
requir
activ
chemotherapi
radiat
immunosuppress
definit
infiltr
chest
radiograph
enrol
systol
blood
pressur
mm
hg
band
form
peripher
blood
exclud
infiltr
consid
definit
character
unequivoc
radiolog
report
person
clinic
diagnosi
pneumonia
admiss
ambigu
chest
radiograph
find
possibl
infiltr
infiltr
versu
atelectasi
exclud
patient
condit
known
increas
pct
level
ie
trauma
renal
failur
pancreat
receiv
antibiot
prior
admiss
exclud
subject
healthcar
repres
provid
written
inform
consent
studi
approv
rgh
univers
rochest
institut
review
board
enrol
conduct
morn
within
hour
admiss
enrol
demograph
clinic
laboratori
inform
nose
throat
swab
specimen
pcr
collect
serum
sampl
collect
admiss
least
hour
later
pct
test
subject
stratifi
presenc
copd
randomli
assign
ratio
use
block
receiv
standard
care
intervent
notat
place
emr
subject
indic
studi
particip
subject
randomli
assign
intervent
group
pct
viral
test
perform
immedi
subject
standard
care
group
sampl
frozen
test
studi
termin
standard
care
test
bacteri
viral
cultur
respiratori
sampl
hospit
influenzarsv
duplex
pcr
hospit
pcr
urin
legionella
antigen
analysi
obtain
discret
provid
team
turnaround
time
hospit
pcr
gener
hour
sampl
receiv
urin
pneumococc
antigen
avail
hospit
studi
period
antibiot
decis
made
attend
physician
without
intervent
investig
standard
care
diagnost
test
bacteri
viral
cultur
respiratori
sampl
hospit
pcr
urin
legionella
antigen
analys
order
discret
careprovid
team
serum
pct
viralatyp
pathogen
pcr
test
perform
soon
possibl
two
serum
pct
level
obtain
higher
use
algorithm
interpret
data
analysi
result
report
emr
hour
enrol
treat
team
notifi
text
sent
via
page
simultan
email
provid
pct
algorithm
algorithm
also
avail
hospit
websit
previous
distribut
pocket
card
follow
inform
commun
serum
pct
biomark
associ
bacteri
infect
use
guid
therapi
accord
highest
valu
admiss
hour
howev
pct
substitut
clinic
judgment
pct
valu
ngml
initi
antibiot
treatment
strongli
discourag
valu
ngml
initi
discourag
valu
ngml
initi
encourag
valu
ng
ml
initi
strongli
encourag
studi
personnel
review
emr
daili
discharg
attent
antibiot
use
safeti
outcom
progress
new
pneumonia
lung
abscess
empyema
icu
care
respiratori
failur
death
seriou
advers
event
sae
defin
icu
transfer
death
within
day
enrol
sae
review
independ
data
safeti
monitor
board
subject
contact
phone
day
month
personnel
blind
random
collect
inform
healthcar
util
antibiot
use
complic
return
baselin
health
serum
pct
level
measur
vida
brahm
biomerieux
use
enzymelink
fluoresc
assay
techniqu
assay
rang
ngml
nose
throat
swab
specimen
test
use
film
array
respiratori
panel
filmarray
idaho
technolog
salt
lake
citi
utah
detect
common
respiratori
virus
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
influenza
viru
influenza
b
viru
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
respiratori
syncyti
viru
atyp
bacteria
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
feasibl
end
point
trial
abil
recruit
randomli
assign
subject
period
primari
impact
end
point
durat
antibiot
therapi
day
antibiot
therapi
defin
day
dose
antibiot
administ
measur
antibiot
exposur
includ
discontinu
antibiot
within
hour
discharg
receiv
antibiot
seven
subject
discharg
receiv
longterm
antibiot
therapi
antiinflammatori
properti
exclud
analys
compar
number
subject
discharg
receiv
antibiot
safeti
assess
hospit
stay
month
safeti
end
point
includ
length
hospit
stay
month
discharg
respiratori
complic
icu
care
death
healthcar
util
sampl
size
chosen
ensur
feasibl
pilot
studi
therefor
formal
sampl
size
power
calcul
perform
categor
variabl
summar
count
proport
compar
use
fisher
exact
test
median
interquartil
rang
iqr
use
describ
continu
variabl
comparison
perform
use
nonparametr
wilcoxon
test
intervent
patient
pct
level
ngml
logist
regress
use
model
algorithm
complianc
function
clinic
covari
includ
age
length
symptom
prior
admiss
sputum
cultur
result
sign
symptom
ill
admiss
diagnosi
chest
radiograph
result
pct
level
viral
test
sa
use
analys
test
perform
level
plan
sampl
size
subject
achiev
month
octob
april
hospit
patient
assess
elig
patient
randomli
assign
intervent
group
randomli
assign
nonintervent
group
figur
group
well
match
demograph
characterist
underli
medic
condit
admiss
diagnos
sever
ill
except
significantli
greater
percentag
patient
chf
randomli
assign
nonintervent
group
tabl
common
admiss
diagnos
group
acut
exacerb
copd
asthma
exacerb
pneumonia
chf
influenza
overal
viral
diagnos
intervent
group
nonintervent
group
made
mean
subject
subject
distinct
virus
filmarray
test
perform
intervent
subject
studi
period
nonintervent
subject
studi
complet
intervent
group
hospit
pcr
detect
influenza
viru
rsv
wherea
filmarray
test
detect
viral
rna
notabl
nonintervent
subject
posit
result
hospit
pcr
avail
treat
physician
common
virus
detect
influenza
viru
case
rhinoviru
rsv
human
coronaviru
human
metapneumoviru
major
patient
group
low
admiss
pct
valu
ngml
tabl
intervent
patient
data
serum
pct
level
admiss
data
subsequ
measur
perform
day
hospit
intervent
subject
initi
low
pct
valu
higher
second
level
result
intervent
subject
pct
valu
ngml
time
point
bacteri
diagnos
made
among
patient
made
basi
sputum
cultur
result
associ
high
pct
level
ngml
three
patient
posit
result
filmarray
assay
atyp
bacteria
ill
associ
low
serum
pct
level
bacteri
blood
cultur
perform
subject
arm
neg
result
except
involv
nonintervent
patient
streptococcu
pneumonia
bacteremia
ill
associ
high
serum
pct
level
admiss
antibiot
exposur
measur
basi
discontinu
antibiot
treatment
within
hour
discharg
receiv
oral
antibiot
total
durat
therapi
tabl
signific
differ
durat
antibiot
therapi
intervent
nonintervent
patient
although
trend
toward
decreas
number
intervent
patient
discharg
receiv
antibiot
vs
p
tabl
antibiot
exposur
intervent
subgroup
presum
lowest
risk
bacteri
infect
ie
patient
test
posit
viru
low
pct
level
compar
nonintervent
group
note
trend
toward
fewer
day
antibiot
prescrib
median
day
iqr
day
vs
day
iqr
day
p
figur
flow
patient
studi
reason
exclus
studi
includ
intens
care
unit
icu
stay
antibiot
use
hour
prior
enrol
activ
chemotherapi
condit
known
increas
procalcitonin
level
eg
renal
failur
pancreat
trauma
definit
infiltr
chest
radiograph
accord
radiolog
report
band
peripher
blood
smear
systol
blood
pressur
sbp
mm
hg
enrol
abbrevi
pct
procalcitonin
significantli
fewer
patient
discharg
receiv
antibiot
vs
p
tabl
figur
analysi
antibiot
use
among
subject
treat
physician
adher
algorithm
reveal
significantli
shorter
durat
therapi
compar
durat
among
nonintervent
subject
median
day
iqr
day
vs
day
iqr
day
p
tabl
consist
find
intervent
subject
low
pct
valu
less
like
receiv
antibiot
hour
discharg
high
pct
level
tabl
total
durat
antibiot
therapi
also
shorter
subject
low
pct
level
median
day
iqr
day
vs
day
iqr
day
p
tabl
howev
patient
high
pct
valu
also
higher
score
median
iqr
vs
iqr
p
greater
percentag
show
possibl
infiltr
chest
radiograph
vs
p
addit
subgroup
analys
assess
ad
valu
viral
test
pct
algorithm
perform
patient
known
viral
diagnosi
hospit
intervent
group
nonintervent
group
less
frequent
discharg
receiv
antibiot
vs
p
trend
toward
shorter
durat
therapi
median
day
iqr
day
vs
day
iqr
day
p
tabl
compar
without
viral
diagnosi
also
investig
possibl
studi
effect
nonintervent
arm
result
prestudi
educ
session
subject
arm
receiv
care
provid
primari
outcom
nonintervent
group
compar
match
histor
control
subject
hospit
rgh
lrti
surveil
studi
deem
use
ident
criteria
low
risk
bacteri
infect
signific
differ
demograph
characterist
admiss
diagnos
tabl
safeti
assess
hospit
stay
month
death
occur
hospit
sae
occur
arm
studi
none
judg
relat
intervent
one
intervent
patient
nonintervent
patient
develop
new
case
pneumonia
within
day
median
length
hospit
stay
day
group
number
posthospit
healthcar
visit
similar
note
length
ill
assess
onset
symptom
prior
hospit
subject
report
return
baselin
shorter
intervent
patient
median
day
iqr
day
vs
day
iqr
day
p
potenti
antibiot
advers
event
rash
gastrointestin
symptom
fungal
overgrowth
resist
flora
intervent
arm
nonintervent
arm
three
case
clostridium
difficil
coliti
occur
nonintervent
patient
compar
none
intervent
group
month
signific
differ
clinic
safeti
outcom
intervent
arm
subgroup
algorithmadher
intervent
subject
compar
nonintervent
patient
overal
algorithm
adher
although
provid
like
prescrib
antibiot
patient
high
pct
valu
withhold
antibiot
patient
low
pct
valu
figur
major
provid
follow
algorithm
recommend
continu
antibiot
treatment
pct
valu
high
although
notabl
antibiot
therapi
discontinu
subject
high
pct
valu
contrast
provid
follow
algorithm
recommend
discontinu
antibiot
subject
low
pct
valu
detect
variabl
associ
algorithm
nonadher
subject
low
pct
valu
admiss
diagnosi
pneumonia
vs
p
first
studi
combin
pct
measur
molecular
viral
diagnost
test
well
first
random
clinic
trial
perform
sole
unit
state
evalu
pctguid
care
patient
hospit
respiratori
ill
although
overal
antibiot
exposur
similar
intervent
nonintervent
arm
subgroup
analys
comparison
histor
control
encourag
suggest
us
physician
respond
viral
biomark
data
inform
antibiot
use
primari
goal
studi
evalu
feasibl
conduct
random
clinic
trial
pctguid
antibiot
recommend
unit
state
data
clearli
indic
trial
like
well
receiv
sinc
complet
enrol
achiev
month
earli
evid
mount
pctguid
treatment
respiratori
infect
safe
reduc
antibiot
use
european
trial
perform
varieti
set
includ
emerg
depart
primari
care
offic
hospit
icu
prior
studi
antibiot
use
decreas
without
harm
measur
composit
advers
event
outcom
largest
trial
date
swiss
multicent
random
trial
pctguid
therapi
hospit
patient
lrti
decreas
overal
antibiot
exposur
report
without
notabl
differ
provid
respons
procalcitonin
pct
guid
treatment
algorithm
circl
repres
individu
pct
valu
intervent
studi
subject
horizont
bar
repres
threshold
pct
valu
ngml
defin
level
either
low
high
algorithm
discourag
antibiot
use
threshold
recommend
antibiot
valu
level
result
segreg
provid
respons
algorithm
design
algorithm
follow
algorithm
reject
shortterm
longterm
outcom
current
use
pct
level
unit
state
approv
manag
sepsi
us
data
pctguid
care
patient
lrti
come
proreal
studi
observ
surveil
antibiot
prescrib
practic
pct
test
made
avail
one
us
hospit
swiss
center
french
center
patient
evalu
unit
state
adher
algorithm
significantli
lower
percentag
among
algorithmexperienc
european
center
suggest
experi
increas
confid
complianc
approach
contrast
studi
examin
benefit
viral
test
reduc
unnecessari
antibiot
use
larg
observ
random
clinic
trial
date
perform
children
demonstr
significantli
less
antibiot
use
diagnost
test
children
whose
rapid
influenza
test
result
made
avail
provid
compar
whose
inform
withheld
although
limit
small
sampl
size
studi
suggest
test
viral
pathogen
addit
influenza
viru
may
reduc
antibiot
use
confid
pctguid
algorithm
among
us
physician
like
iter
process
focus
patient
nonpneumon
lrti
low
risk
bacteri
infect
use
standard
clinic
paramet
adher
pct
algorithm
encourag
given
low
us
complianc
rate
studi
albrich
et
al
howev
despit
rel
good
complianc
popul
enrich
subject
low
risk
bacteri
complic
see
signific
differ
antibiot
use
intervent
nonintervent
arm
suspect
result
part
due
signific
studi
effect
result
decreas
antibiot
exposur
nonintervent
patient
support
conclus
overal
decreas
durat
antibiot
therapi
nonintervent
subject
compar
durat
similar
histor
control
studi
effect
like
multifactori
includ
prestudi
educ
session
spillov
care
result
provid
care
patient
arm
increas
awar
viral
activ
commun
last
provid
also
awar
behavior
observ
may
result
hawthorn
effect
studi
number
limit
trial
design
feasibl
pilot
small
sampl
size
definit
conclus
drawn
subgroup
analys
particularli
addit
valu
viral
test
pctguid
therapi
moreov
studi
power
determin
noninferior
pctguid
care
compar
standard
treatment
algorithm
howev
like
european
trial
detect
major
safeti
signal
prohibit
proceed
larger
clinic
trial
second
repeat
pct
measur
sever
day
hospit
perform
may
ad
valu
decreas
antibiot
use
addit
routin
avail
hospit
pcr
may
dilut
effect
multiplex
viral
test
last
use
histor
control
evalu
studi
effect
address
chang
practic
may
occur
unrel
studi
nevertheless
lesson
learn
studi
facilit
design
larger
definit
us
trial
although
studi
clearli
demonstr
feasibl
perform
pct
trial
unit
state
number
factor
need
consider
first
hospit
stay
nonpneumon
lrti
tend
brief
thu
opportun
interven
limit
maxim
impact
antibiot
exposur
intervent
begin
earli
ideal
emerg
depart
second
algorithm
adher
need
improv
although
clinic
judgment
remain
cornerston
good
medic
care
complianc
goal
futur
trial
therefor
incorpor
strategi
influenc
physician
behavior
use
antibiot
stewardship
team
reinforc
pct
algorithm
recommend
studi
effect
appear
import
impedi
demonstr
signific
differ
antibiot
exposur
independ
effect
viral
test
futur
trial
may
need
use
separ
compar
studi
site
intervent
nonintervent
group
final
safeti
pctguid
care
patient
lrti
lower
risk
bacteri
infect
establish
use
also
explor
subject
pneumon
diseas
conclus
despit
modest
chang
antibiot
exposur
observ
primari
analysi
result
subgroup
analys
comparison
histor
control
encourag
suggest
us
physician
respond
viral
biomark
data
ultim
studi
need
assess
valu
viral
test
determin
role
pctguid
care
practic
effect
treatment
protocol
patient
admit
nonpneumon
respiratori
ill
